Investigation of satisfaction, efficacy and safety after switching from daily GLP-1 receptor agonist to weekly dulaglutide in patients with type 2 diabetes -open label, randomized, parallel group controlled clinical study-

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dulaglutide (Primary) ; Efinopegdutide
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

23 Aug 2017 Status changed from active, no longer recruiting to completed.
20 Jul 2017 Planned End Date changed from 30 Nov 2018 to 11 Jul 2017.
24 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight